LAVA Therapeutics N.V. (LVTX)
NASDAQ: LVTX · Real-Time Price · USD
1.430
+0.030 (2.14%)
At close: Jul 18, 2025, 4:00 PM
1.420
-0.010 (-0.70%)
After-hours: Jul 18, 2025, 4:04 PM EDT

LAVA Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202019
Period Ending
Jul '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
37254292142-
Upgrade
Market Cap Growth
-61.84%-39.79%-54.86%-35.10%--
Upgrade
Enterprise Value
-29-48-5744-
Upgrade
Last Close Price
1.420.951.583.505.50-
Upgrade
PS Ratio
7.642.096.144.7526.50-
Upgrade
PB Ratio
1.450.900.811.071.20-
Upgrade
P/TBV Ratio
1.450.900.811.071.20-
Upgrade
P/FCF Ratio
---26.62--
Upgrade
P/OCF Ratio
---22.76--
Upgrade
EV/Sales Ratio
---0.200.81-
Upgrade
EV/FCF Ratio
---1.13--
Upgrade
Debt / Equity Ratio
0.010.190.120.060.040.54
Upgrade
Debt / FCF Ratio
---1.58--
Upgrade
Asset Turnover
0.060.130.060.140.070.26
Upgrade
Quick Ratio
6.424.256.426.2011.912.36
Upgrade
Current Ratio
6.734.406.646.4012.142.48
Upgrade
Return on Equity (ROE)
-73.21%-63.49%-60.95%-31.22%-67.24%-236.57%
Upgrade
Return on Assets (ROA)
-23.02%-17.67%-22.13%-15.41%-34.13%-62.63%
Upgrade
Return on Capital (ROIC)
-47.27%-35.63%-36.41%-20.28%-40.40%-94.97%
Upgrade
Earnings Yield
-74.92%-100.42%-100.80%-34.68%-29.88%-
Upgrade
FCF Yield
-81.24%-78.24%-98.74%3.76%-20.75%-
Upgrade
Buyback Yield / Dilution
-0.00%-0.38%-3.12%-31.21%-4850.36%10.81%
Upgrade
Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q